Drug profile

The FDA adverse-event record for Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

444 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract. See the species affected, top reactions, and outcomes below.

444
adverse-event reports
3.6%
death-coded share
Dog
most-reported species
235
Lack of efficacy (bacteria) - Borrelia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
444
Total Reports
16
Deaths Reported
3.6%
Death Rate

Active Ingredients

Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract

Administration Routes

SubcutaneousParenteralUnknownOtherOralAuricular (Otic)

Species Affected

Dog 444

Most Affected Breeds

Retriever - Labrador 75
Retriever - Golden 49
Shepherd Dog - German 24
Crossbred Canine/dog 24
Shepherd Dog - Australian 16
Siberian Husky 14
Shih Tzu 11
Poodle (unspecified) 11
Pit Bull 9
Boxer (German Boxer) 8

Most Reported Reactions

Lack of efficacy (bacteria) - Borrelia 235
Other abnormal test result NOS 88
Lack of efficacy (ectoparasite) - tick NOS 81
Vomiting 42
Diarrhoea 33
Lethargy (see also Central nervous system depression in Neurological) 30
Partial lack of efficacy 26
Lethargy (see also Central nervous system depression in 'Neurological') 23
Lack of efficacy (bacteria) - Anaplasma 21
Lameness 18
Not eating 17
Proteinuria 15

Outcome Breakdown

Outcome Unknown
318 (71.6%)
Ongoing
57 (12.8%)
Recovered/Normal
53 (11.9%)
Euthanized
11 (2.5%)
Died
5 (1.1%)

Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract Adverse Event Insights

444 reports name Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract; 16 recorded a death outcome (3.6% of reported events, not a population-level mortality rate). Active ingredient: Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract. Administration routes: Subcutaneous, Parenteral, Unknown, Other.

By species: Dog (444 reports). By breed: Retriever - Labrador (75), Retriever - Golden (49), Shepherd Dog - German (24).

Leading clinical signs: Lack of efficacy (bacteria) - Borrelia (235), Other abnormal test result NOS (88), Lack of efficacy (ectoparasite) - tick NOS (81), Vomiting (42). Outcome, 444 coded reports: Outcome Unknown leads at 71.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.